{"links":{"html":"https://www.erudio.com/reports/ribolaris-nct05296746","json":"https://www.erudio.com/reports/ribolaris-nct05296746.json","markdown":"https://www.erudio.com/reports/ribolaris-nct05296746.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"ribolaris-05296746"}},"request":"https://www.erudio.com/contact?report=ribolaris-05296746"},"offer":{"cited_commentary_sources":31,"verified_hcp_statements":139,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":18,"optional":true,"price_per_verified_person_usd":15,"price_usd":270,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"ribolaris-nct05296746"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=ribolaris-05296746","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/ribolaris-nct05296746","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-30T02:11:00.323745Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":0},"aspects":[{"claim_count":13,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":8,"title":"Primary endpoint: Distant metastasis-free survival (DMFS) in the ROR-low cohort (responder cohort)"},{"claim_count":17,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":15,"title":"Secondary endpoints"},{"claim_count":14,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":8,"title":"Population and setting"},{"claim_count":8,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":6,"title":"The comparison"},{"claim_count":13,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":9,"title":"Safety and tolerability"},{"claim_count":22,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":11,"title":"Design and conduct"},{"claim_count":15,"coverage":"discussed","id":"A1","source_count":9,"title":"Dynamic genomic response, assay comparability and monitoring simplicity"},{"claim_count":17,"coverage":"discussed","id":"A2","source_count":8,"title":"Clinical readiness and selective implementation"},{"claim_count":14,"coverage":"discussed","id":"A3","source_count":11,"title":"Addition versus substitution and the rationale from earlier studies"},{"claim_count":11,"coverage":"discussed","id":"A4","source_count":1,"title":"Duration, persistence, overall survival and cumulative treatment burden"},{"claim_count":8,"coverage":"discussed","id":"A5","source_count":2,"title":"ctDNA-guided sparing and options for inadequate responders"},{"claim_count":7,"coverage":"discussed","id":"A6","source_count":2,"title":"Patient priorities, quality of life and local treatment"},{"claim_count":14,"coverage":"discussed","id":"A7","source_count":10,"title":"Research engagement, expansion and anticipated evidence"},{"claim_count":2,"coverage":"discussed","id":"A8","source_count":1,"title":"Publication-status dispute and allegations about transparency and harm"}],"counts":{"cited_sources":32,"claims_by_expression_type":{"comparison":10,"experience":6,"interpretation":33,"opinion":27,"primary_context":10,"question":13,"restatement":20,"uncertainty":13,"unspecified":7},"claims_by_kind":{"publication_statement":27,"source_observation":112},"clinician_statements":17,"evidence_units":121,"findings":10,"organisational_accounts":1,"people_cited":25,"people_identity_verified":18,"people_total":26,"screened_sources":45,"verified_claims":139},"findings_index":[{"id":"F1","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":4,"views":8},"has_counterview":true,"limitations":3,"links":{"context":0,"support":14},"ma_question":true,"named_voices":10,"passages":13,"sources":13,"sources_by_kind":{"commentary":12,"media":1}},"title":"An encouraging molecular response is not yet evidence that chemotherapy can safely be omitted"},{"id":"F2","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":0,"questions":4,"restated":3,"views":2},"has_counterview":true,"limitations":3,"links":{"context":1,"support":10},"ma_question":true,"named_voices":2,"passages":8,"sources":5,"sources_by_kind":{"commentary":1,"media":3,"publication":1}},"title":"Eligibility and the historical benchmark are a specific methodological challenge"},{"id":"F3","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":1,"questions":3,"restated":3,"views":3},"has_counterview":true,"limitations":3,"links":{"context":0,"support":13},"ma_question":true,"named_voices":8,"passages":10,"sources":8,"sources_by_kind":{"commentary":6,"media":2}},"title":"Dynamic genomic selection appeals, but assay comparability and response meaning remain open"},{"id":"F4","structure":{"claims":13,"claims_by_group":{"comparisons":4,"experience":1,"questions":1,"restated":1,"views":6},"has_counterview":false,"limitations":3,"links":{"context":1,"support":13},"ma_question":true,"named_voices":6,"passages":10,"sources":10,"sources_by_kind":{"commentary":7,"media":3}},"title":"Earlier trials motivate chemotherapy replacement; adjuvant add-on evidence does not establish it"},{"id":"F5","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":8},"has_counterview":true,"limitations":3,"links":{"context":0,"support":12},"ma_question":true,"named_voices":7,"passages":12,"sources":8,"sources_by_kind":{"commentary":6,"media":1,"publication":1}},"title":"Interest in selective clinical use is accompanied by explicit nonstandard-care boundaries"},{"id":"F6","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":3,"views":8},"has_counterview":true,"limitations":2,"links":{"context":0,"support":14},"ma_question":true,"named_voices":7,"passages":14,"sources":9,"sources_by_kind":{"commentary":6,"media":2,"publication":1}},"title":"Perceived tolerability advantages coexist with substantial hematologic and hepatic toxicity"},{"id":"F7","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":0,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":3,"passages":7,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Overall survival, duration, cost and cumulative treatment burden remain linked questions"},{"id":"F8","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":1,"views":4},"has_counterview":false,"limitations":2,"links":{"context":2,"support":7},"ma_question":true,"named_voices":4,"passages":8,"sources":2,"sources_by_kind":{"commentary":2}},"title":"ctDNA-guided de-escalation is attractive but not yet actionable; nonresponder combinations have safety constraints"},{"id":"F9","structure":{"claims":15,"claims_by_group":{"comparisons":0,"experience":3,"questions":3,"restated":1,"views":8},"has_counterview":false,"limitations":3,"links":{"context":0,"support":16},"ma_question":true,"named_voices":7,"passages":13,"sources":9,"sources_by_kind":{"commentary":6,"media":2,"publication":1}},"title":"Rapid engagement is interpreted as demand for de-escalation, not measured patient preference"},{"id":"F10","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":2,"passages":2,"sources":1,"sources_by_kind":{"commentary":1}},"title":"A separate thread contains consequential but unsubstantiated allegations of harmful intent"}],"medical_affairs_question":"What long-term disease control and patient-valued trade-offs would justify chemotherapy omission in this response-defined population?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Molecular response is being welcomed, while chemotherapy-omission safety remains the unresolved clinical question"},{"id":"section-2","level":2,"title":"Eligibility and historical comparison determine what a favorable DMFS result would mean"},{"id":"section-3","level":2,"title":"Dynamic genomic selection is attractive without making assays interchangeable"},{"id":"section-4","level":2,"title":"Prior evidence supplies a rationale for substitution, not proof of survival equivalence"},{"id":"section-5","level":2,"title":"Selective-use interest stops short of routine-care endorsement"},{"id":"section-6","level":2,"title":"Less toxic is a comparative assessment, not an absence of consequential toxicity"},{"id":"section-7","level":2,"title":"Duration and overall survival frame the cumulative benefit–burden discussion"},{"id":"section-8","level":2,"title":"ctDNA is a proposed route to sparing treatment, not an actionable standard"},{"id":"section-9","level":2,"title":"Engagement indicates a valued question, but does not measure patient trade-offs"},{"id":"section-10","level":2,"title":"Serious allegations in one thread remain allegations"},{"id":"section-11","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, parallel, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F9","shared_claims":1}],"id":"T1","label":"Primary endpoint: Distant metastasis-free survival (DMFS) in the ROR-low cohort (responder cohort)"},{"findings":[{"id":"F1","shared_claims":8},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":4}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":4},{"id":"F5","shared_claims":4},{"id":"F6","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":2}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F6","shared_claims":10},{"id":"F8","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":3},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":3},{"id":"F9","shared_claims":5}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-30T02:11:00.323745Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-30T02:22:55Z","record_hash":"ecc1563863c6524015fa3ad0ee01d65925ffbc49fa7089dc4ebe22097fd1e36b","release_hash":"527664bb4f5dd36bf9186b2ff479669319dbc54ac212c18dc6cf9fcaddf73a5c","report_id":"erudio-nct05296746","run_id":"8a509184-f19f-451c-b859-1e85f50223d6","schema_version":"5.0","slug":"ribolaris-05296746","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"RIBOLARIS asks whether response to neoadjuvant ribociclib plus endocrine therapy can guide chemotherapy omission for patients with clinically high-risk stage II HR-positive/HER2-negative breast cancer. A LinkedIn poster welcomes the study and keeps response-guided omission conditional. In a LinkedIn post, eligibility and historical comparisons are questioned. Long-term clinical validation remains open in the welcoming poster's assessment. The sources reviewed for this edition place RIBOLARIS's preliminary interim-analysis results at ESMO 2025.","meta_description":"45 sources screened · 139 verified statements (17 from clinicians verified by NPI or staff page) from 32 sources · 10 findings. Updated Oct 30, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-f2d53ba3d576ecd1cf6f"],"id":"F2","paraphrase":"A LinkedIn poster asked how trial eligibility aligns with the population used for the historical MINDACT comparison.","publication_caveats":{"reason":"Publication caveats are not specified in the sources reviewed for this edition.","status":"not_set"},"source_channel":"linkedin_post","source_date":"2025-10-21","title":"Eligibility and the historical benchmark are a specific methodological challenge"},{"cited_claim_ids":["claim-af4c9cf57d8452da39cc"],"id":"F3","paraphrase":"An X poster asked how PAM50 ROR's prognostic performance compares with MammaPrint and Oncotype.","publication_caveats":{"reason":"Publication caveats are not specified in the sources reviewed for this edition.","status":"not_set"},"source_channel":"x_thread","source_date":"2022-04-22","title":"Dynamic genomic selection appeals, but assay comparability and response meaning remain open"}]},"publication":{"approved_at":"2026-10-30T02:22:55Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":45},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","54 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are not representative of all HCP discussion. Identifier-focused searches may miss unnamed references or wording variants, and several passages have not been fully assessed for clinician views.","Institutional relays, reposts, repeated wording and accounts from people described as involved in RIBOLARIS do not represent independent confirmations or a count of distinct HCP opinions.","Long-term RIBOLARIS recurrence and survival outcomes are not reported in the reviewed commentary. The available publication describes rationale and design rather than observed trial outcomes.","Some named authors' clinical roles or identities are not independently established. Anonymous spoken commentary remains attributed to its source, not to a presumed host or presenter.","Earlier and later accounts describe different enrollment plans and use differing eligibility or endpoint language. These dated descriptions should not be silently merged.","No separate trial protocol or exact matching regulatory-label documents were available. Absence of those documents does not establish absence of approval.","The harmful-intent and data-concealment accusations in one thread are not substantiated by the sources reviewed."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":2,"linkedin_post":6,"other":0,"podcast":1,"publication":1,"registry":0,"regulatory":0,"x_thread":19,"x_video":2,"youtube":1},"by_evidence_role":{"commentary":31,"context":1},"count":32,"evidence_window":{"end":"2026-08-18","start":"2022-04-22"},"retrieval_snapshot":"2026-10-29T20:34:14.336646Z","timeline":[{"count":1,"week":"2022-W16"},{"count":1,"week":"2023-W12"},{"count":1,"week":"2023-W13"},{"count":1,"week":"2023-W15"},{"count":1,"week":"2023-W19"},{"count":2,"week":"2023-W27"},{"count":1,"week":"2024-W20"},{"count":1,"week":"2025-W20"},{"count":1,"week":"2025-W25"},{"count":14,"week":"2025-W42"},{"count":2,"week":"2025-W43"},{"count":1,"week":"2025-W48"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2026-W02"},{"count":2,"week":"2026-W34"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT05296746:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05296746:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42602220","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-6jgjcqlje3nwzcx26s2dtcvl-3m3hdta5enk2r","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zjicmhyujxwzbzne7wtdnjza-3m3filuwros2o","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7053990188758278144","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7384927259247153152","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7384958777684480000","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7385142554133983232","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7386423595289190401","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7430859954913292288","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7495147253704306688","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7495380715644309504","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:9db9b0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1507395010920128538:cea87d18-f6cc-4181-a42e-a339d05012bf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1517495728926609409:4fc45ef9-1e61-4ba8-af5c-0484956efcb6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1639340759978475550:2ba70eb3-9074-4025-a813-7a8c90dd2d54","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1640224877054443520:47f7db0c-07e4-41e7-a96b-ac32cd25edfa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1646800909521895425:bb6a417f-9d42-4fab-a747-05cc928304d6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1656885187773448195:ddde36d5-e9a6-4957-aaf1-e38480b1cba2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1670793594137985030:0ce0fdc7-9bea-4a25-9ced-df5388f979c9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1677051541558120451:5c58e180-6706-48b4-a1f9-76225f915844","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1677218293516468224:508a4a96-3c9c-4b33-bc97-dc1fb1a24ac2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1677320652796166145:4f9089e3-58a7-4c33-a9ef-73837cdac48d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1791377944113238405:0cbf3810-6f61-4102-ab7a-086f3a0f7266","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1922998705805820102:d296f494-23c8-4d3a-a1c6-91acd97d0cac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1934554730274885706:43ebf0d2-1576-4601-b83c-2c98982f8df2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1953360439112352071:9a7e4118-e257-4add-94be-1232d8d17fdf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979158146967887984:59977c5c-e457-44c5-816c-9f09625e9a0f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979158165208875328:7b80f870-c55b-4760-808b-0080b248d416","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979158592709128686:9ae029ed-c774-48b9-9339-4919fbc52971","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979158593807991223:2ac1737f-9094-46fb-bcca-707647129413","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979158642457825751:509bdc7a-166e-40cc-bab2-42ea16caa7ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979159783622971834:ef60e2f1-2bbf-402b-9f54-b95736b2a311","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979161770804617461:b870f8e4-7bd2-48d6-95d1-3736c36e9302","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979163815989141770:d82cbd83-36a1-4327-a494-897cd050015e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979163876760363345:44f654c1-4eb5-42f1-9cc1-c015ed079a29","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979165279889358912:70e52a25-3646-4daf-ab7c-7dd6dc905b57","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979167937865945215:63788d67-9e35-4481-b677-b0b974a0a43f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979168369250041872:84704071-39a5-48c4-ba59-cbb5c3db34ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979182931617755442:4a7b113e-5ff8-4690-aa59-84499393f596","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980638662569136227:7b2beaa1-ba58-4fcc-b76a-6dd7f29861ac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980765821526806684:5e744386-db30-4e92-a07c-d03cb15145b8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2008185870361178341:83746876-12e7-4f84-ae1c-fe07de4984ce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2025091823975235977:5459fd43-2731-4248-bf8b-0dd136555ebe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:1646800909521895425","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:1980638662569136227","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Gifu0X7P-JM","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":2,"linkedin_post":8,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":31,"x_video":2,"youtube":1},"by_evidence_role":{"commentary":45},"count":45,"evidence_window":{"end":"2026-08-18","start":"2022-03-25"},"retrieval_snapshot":"2026-10-29T20:34:14.336646Z","timeline":[{"count":1,"week":"2022-W12"},{"count":1,"week":"2022-W16"},{"count":1,"week":"2023-W12"},{"count":1,"week":"2023-W13"},{"count":2,"week":"2023-W15"},{"count":1,"week":"2023-W16"},{"count":1,"week":"2023-W19"},{"count":1,"week":"2023-W25"},{"count":3,"week":"2023-W27"},{"count":1,"week":"2024-W20"},{"count":1,"week":"2025-W20"},{"count":1,"week":"2025-W25"},{"count":1,"week":"2025-W32"},{"count":18,"week":"2025-W42"},{"count":4,"week":"2025-W43"},{"count":1,"week":"2025-W48"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2026-W02"},{"count":2,"week":"2026-W08"},{"count":2,"week":"2026-W34"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Kisqali"],"label":"ribociclib","slug":"ribociclib"},{"reason":"Unmapped registry intervention: chemotherapy (adjuvant)","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Breast Cancer Stage II","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"RIBOLARIS","aliases":["RIBOLARIS","Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer","Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer"],"brief_title":"Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer","collaborators":["Novartis","UNICANCER"],"conditions":["Breast Cancer Stage II"],"display_condition":"clinically high-risk stage II ER+/HER2- breast cancer","display_interventions":[["ribociclib"]],"enrollment":{"count":1100,"type":"ESTIMATED"},"interventions":[{"name":"Ribociclib (neoadjuvant)","synonyms":["Kisqali"],"type":"DRUG"},{"name":"Chemotherapy (adjuvant)","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Ribociclib (adjuvant)","synonyms":["Kisqali"],"type":"DRUG"}],"nct_id":"NCT05296746","official_title":"Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2029-10-01","type":"ESTIMATED"},"primary_endpoints":[{"description":"DMFS is defined as the time from date of surgery to date of first event of distant metastatic recurrence or death (any cause).","measure":"Distant metastasis-free survival (DMFS) in the ROR-low cohort (responder cohort)","timeFrame":"Until recurrence (if it happens) for a maximum of 7.5 years of follow-up"}],"registered_date":{"date":"2022-03-25","type":"ACTUAL"},"registry_last_updated":"2026-05-14","registry_url":"https://clinicaltrials.gov/study/NCT05296746","short_name":"RIBOLARIS","short_name_basis":"registry_acronym","sponsor":"SOLTI Breast Cancer Research Group","start_date":{"date":"2022-05-03","type":"ACTUAL"},"study_design":"interventional, non randomized, parallel, phase2","study_ids":[{"id":"SOLTI-1911","type":"sponsor_study_id"},{"domain":"BIG","id":"BIG-21-02","type":"other"}],"study_type":"INTERVENTIONAL"}}}